论文部分内容阅读
目的评价索拉非尼联合胸腺肽α1治疗晚期肝细胞肝癌(HCC)的疗效。方法 40例晚期HCC患者随机均分两组:A组口服索拉非尼(400mg,2次/d);B组加用胸腺肽α1(1.6mg,2次/周)。每4周为一周期。三周期后评估疗效(RECIST标准)和毒性反应(NCI-CTC标准)。结果 B组疾病控制率(DCR)、中位肿瘤进展时间(mTTP)、中位总生存期(mOS)、CD3+、CD4+、CD8+、CD4+/CD8+、CD8+/CD28+、CD16+/CD56+均明显高于A组(P<0.05)。结论索拉非尼联合胸腺肽α1治疗晚期HCC能明显提高患者的免疫功能。
Objective To evaluate the efficacy of sorafenib combined with thymosin α1 in the treatment of advanced hepatocellular carcinoma (HCC). Methods Forty patients with advanced HCC were randomly divided into two groups: group A received sorafenib (400 mg twice daily), and group B received thymosin α1 (1.6 mg twice daily). Every 4 weeks for a period. Three cycles after the evaluation of efficacy (RECIST standard) and toxicity (NCI-CTC standard). Results The disease control rate (DCR), median tumor progression time (mTTP), median overall survival (mOS), CD3 +, CD4 +, CD8 +, CD4 + / CD8 +, CD8 + / CD28 + and CD16 + / CD56 + in group B were significantly higher than those in group A Group (P <0.05). Conclusion Sorafenib combined with thymosin α1 in advanced HCC patients can significantly improve the immune function.